Novartis gets breakthrough therapy status for sickle cell disease treatment crizanlizumab

This article was originally published here

Crizanlizumab (SEG101) is a humanized anti-P-selectin monoclonal antibody being studied to restrict VOCs in SCD. The status has been provided based on positive data from the phase II

The post Novartis gets breakthrough therapy status for sickle cell disease treatment crizanlizumab appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply